May 21, 2010
Posted by on
A slightly different FSR this week with a spotlight on Global Health, right on the heels of the recent Grand Challenges Canada announcement. An interesting report in Nature Biotechnology, led by Drs. Abdallah Daar and Peter Singer at the McLaughlin-Rotman Centre for Global Health, mapped the collaborations between health biotech companies in developing countries. The study is a first for tracking “South-South” partnerships and they offer some interesting insights:
South-South collaborations have become a widely chosen path for health biotech companies:
- About a quarter (27%), participate in collaborations with another developing country and many (21%) are involved in multiple initiatives.
- South-North collaborations with developed countries are still more common (53%).
- The most active countries with the highest percentage of firms engaged in South-South collaborations are Cuba (~75%) and South Africa (~45%), followed by Egypt, Brazil, India, and China.
- These leading developing countries in health biotech make up the majority of the linkages (see figure below)
- Many of the collaborations are within their own regions such that they are establishing free trade zones to encourage trade with one another.
South-South Collaboration Network
Some of the motivations for companies in developing to collaborate include:
- Minimizing risk and cost by sharing the burden with a partner.
- Expanding their potential markets with an easier or facilitated access to a foreign market.
- Gaining specific knowledge or skills, particularly since there are many specialized skills and technologies involved in biotech research that may not be available locally.
The nature of the collaborations, however, is mainly end-stage commercialization agreements rather than R&D.
- Distribution agreements (72%) and marketing activities (34%) account for the majority of the collaborations with only 13% involving R&D and 9% involving clinical trials activities.
- Innovation based knowledge sharing would likely have greater long-term benefits and future policies should encourage more of these types of collaborations.
To further promote such initiatives, Government organizations and other third parties can, and should, play a larger role to cultivate joint ventures since the majority of the South-South collaborations were initiated by the participating companies themselves. It is important to realize that South-South collaborations in the biotech sector are just as valuable as North-South collaborations to sustain a growing culture that addresses global health issues.
Also note that this study follows a pair of Nature Biotechnology publications last year by the same group at MRC – one explores “South-North” health biotech collaborations and the other focuses on Canadian biotech collaborations with developing countries.
May 11, 2010
Posted by on
A new nonprofit organization called Grand Challenges Canada has been formed to deploy the Canadian government’s $225 million Development Innovation Fund. In a fabulous marriage of theory and practice, Grand Challenges will be run by Peter Singer, who is also the Director of the McLaughlin-Rotman Centre for Global Health. It also draws on an impressive international scientific advisory board.
The program will identify and launch five “grand challenges” over a 5-year period. The first is
“to create a new class of point-of-care (POC) diagnostics that will be easy to use, low cost, multiplexed and able to assess disease stage and provide information on prognosis.”
Information on the RFP, policies and forms to apply for funding are here, and the deadline for this round of applications is July 12, 2010 at 11:59 pm EST.
Grand Challenges Canada is independent, but is being run in partnership with International Development Research Centre (IDRC), the Canadian Institutes of Health Research (CIHR), the McLaughlin-Rotman Centre for Global Health and with support from the Bill & Melinda Gates Foundation.